Lv41
446 积分 2023-06-05 加入
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
1个月前
已完结
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
1个月前
已完结
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
1个月前
已完结
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
1个月前
已完结
Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug-Drug Interaction Study
1个月前
已完结
Molecular glue CELMoD compounds are regulators of cereblon conformation
1个月前
已完结
Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy
2个月前
已完结
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
2个月前
已完结
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial
2个月前
已完结
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
2个月前
已完结